Potential new therapeutic targets: Association of microRNA with atherosclerotic plaque stability

Abstract

Cardiovascular disease represents a major threat to human health with vascular atherosclerosis contributing significantly to its cause, particularly due to the ease of rupture of atherosclerotic plaques. The stability of atherosclerotic plaques is influenced by a variety of factors, including intraplaque neovascularization, the inflammatory response, smooth muscle cells and macrophages, and core lipid volumes. Thus, the investigation of factors affecting the stability of atherosclerotic plaques is of great significance for the development of new drugs for the treatment of atherosclerotic diseases. MicroRNAs are small single-stranded non-coding RNAs between 17 and 22 nucleotides in length. They are translated together with the untranslated region (UTR) of the target gene mRNA, where the completeness of base-pairing can influence the translation or degradation of the target genes. MicroRNAs can thus regulate gene expression at the post-transcriptional level and have been demonstrated to be extensively involved in the regulation of various factors affecting plaque stability. In this paper, we review microRNA development, factors affecting atherosclerotic plaque stability, and the relationship between microRNAs and plaque stability, with the aim of describing the mechanisms by which microRNAs affect gene and protein expression in relation to atherosclerosis progression (including plaque rupture) to suggest new therapeutic targets for atherosclerotic disease.

Keywords

atherosclerosis MicroRNAs atherosclerotic plaques stroke treatment

Background

Atherosclerosis is the main cause of cardiovascular and cerebrovascular diseases, with the rupture and shedding of unstable plaque leading to atherosclerosis-related complications.^1,2 At present, relevant imaging examinations can only detect lesions showing structural changes and are unable to predict future plaque instability.³ microRNAs are small RNAs that are mainly involved in the regulation of post-transcriptional translation of genes in mammals.⁴ Studies have shown that microRNAs can attach to and silence genes involved in the atherogenesis pathway, thereby inhibiting the expression of proteins and cellular functions involved in regulating the stability of atherosclerotic plaques. It is thus possible that microRNAs may represent new targets for research to prevent and treat atherosclerotic diseases.^5–7 This article aimed to review the role of microRNAs in gene and protein expression in relation to the progression of atherosclerosis, including plaque rupture, to provide new ideas for the prevention of atherosclerotic diseases.

MicroRNA

The discovery of microRNA

In 1993, a small-molecule RNA was first discovered in nematodes. This was found to bind to the non-coding regions of the three ends of target messenger RNAs through complementary base-pairing and thus inhibit the translation of the target mRNA to protein, significantly influencing nematode development; this microRNA was termed miR-LIN4.⁸ Subsequent research revealed that microRNAs represent a class of small single-stranded non-coding RNAs with lengths between 17 and 22 nucleotides, and which are mainly involved in the regulation of post-transcriptional translation of genes in vivo. To date, approximately 1000 human microRNAs have been discovered, accounting for 1% of the total number of human genes. They have been shown to regulate the expression of more than 30% of related target genes at a post-transcriptional level and, consequently, to play significant roles in the modulation of modulate the entire process of human growth and development and the occurrence and development of various diseases.^9,10

Mechanism of microRNA synthesis

The primary product of microRNA transcription in the nucleus is cleaved by the ribozyme DROSHA RNase into a pre-microRNA of 70 nucleotides in length. This is then transported to the cytoplasm by various transporters. In the cytoplasm, the pre-microRNA is cleaved by DICER endonuclease into a double-stranded microRNA with a length between 17 and 22 nucleotides.¹¹ This double-stranded microRNA contains mismatched nucleotide sequences at the 5′ end, resulting in structural instability at the 5′ end, and the eventual formation of a single-stranded microRNA with mature biological functions, most of which are derived from the nucleotide sequence at the 5′ end.¹² In addition, very few microRNAs can be processed from intronic RNAs and exons that have no protein-coding function.^13,14

Mechanism of microRNA interaction with proteins and genes

The biological functions performed by microRNAs involve the silencing of target mRNAs in the cytoplasm, thus inhibiting the expression of target genes, together with acting in the nucleus to bind to the promoter regions of target genes resulting in their silencing or overexpression, or even binding to exosomes that are secreted from the cell and exert specific effects on other cells.¹⁵ microRNAs can also interact with a variety of proteins during maturation. microRNA biogenesis first occurs in the nucleus, where the RNase III complex DROSHA cuts pri-miRNA into pre-microRNA. Once the pre-microRNAs are exported to the cytoplasm by Exportin 5, the RNase III complex DICER/TARBP2 recognizes their hairpin-like structures and processes them to produce mature microRNAs of approximately 22 nucleotides in length. The mature microRNA is then loaded onto AGO2, which promotes the formation of an mRNA-induced silencing complex (RISC). AGO2 and its family members are considered the only RNA-binding proteins that interact with mature microRNAs.^16,17

The interaction between microRNA and microRNA has not been fully defined. Before the discovery of naturally occurring microRNA sponges, some research groups used artificial microRNA sponges as microRNA inhibitors, thereby inhibiting the downstream effects of microRNAs. Studies have shown that microRNAs can target multiple genes, and a single gene can be regulated by multiple microRNAs, indicating co-regulation between microRNAs. For example, studies have found that miR-124 and miR-203 synergically suppressed the ZEB2 pathway associated with the epithelial-mesenchymal transition (EMT) in clear cell renal carcinoma, and synergistic effects between miR-141-3p and miR-145-5p were also observed to regulate target genes in the same tumor.^18–20 Increasing evidence strongly suggests that novel microRNA therapies may have significant potential for the treatment of diseases in the future. Although the modulation of some key microRNAs can successfully reverse the pathological process, it is believed that intrinsic synergistic effects between microRNAs may be more effective in disease treatment.

The relationships between microRNAs and long non-coding RNAs (lncRNAs) are also unclear, although studies have found that there is obvious crosstalk between the two RNA species, leading to binding competition between microRNAs and lncRNAs for their targets. LncRNAs act by isolating microRNAs, leading either to silencing of the microRNA or downregulation of target mRNAs, similar to the action of a sponge that can absorb the microRNA and thus reduce its level. The first evidence of an lncRNA as a functional target of a microRNA is the reverse transcript of the cell proliferation-associated protein CDR1 which is a circular RNA (circRNA) that is perfectly complementary to miR-671.²¹ MiR-671 can modulate the expression of CDR1, suggesting that antisense transcripts of non-coding RNAs can be used directly as microRNA targets, which is an important starting point for the study of the sponge phenomenon. Changes in circRNA abundance can regulate microRNA activity to target genes accordingly. CircRNA sponges contain large numbers of microRNA binding sites. Overexpression of the circRNA leads to downregulation of the microRNA, thus reducing the inhibitory effects of the microRNA on its downstream mRNA targets and reducing the expression of downstream target genes. A study found that circRNA 0003645 showed carcinogenic effects by sponging the removal of miR-1299 in liver cancer cells.²²

Atherosclerotic plaque progression

Atherosclerotic lesions are found mainly in medium and large arteries, such as the aorta and coronary arteries. The normal structure of the arterial wall is made up of three layers, namely, the outermost outer membrane, which is rich in nerve endings, mast cells, and microvessels that function to nourish the outer membrane, the middle membrane layer consisting of quiescent smooth muscle cells, and a well-organized extracellular matrix composed of elastin, collagen, and other macromolecules, and, lastly, the innermost layer, the intima, which is the site of atherosclerotic plaque formation. Damage to the arterial endothelium is caused by various pathogenic risk factors in the earliest stages of atherosclerosis, followed by oxidative modification of low-density lipoprotein (LDL) in the sub-endothelium to form oxidized low-density lipoprotein (ox-LDL). Monocytes can bind to adhesion molecules expressed by activated endothelial cells and chemokines can promote the migration of the monocyte-adhesion molecule complexes within the arterial wall. Monocytes migrate into the endothelium and mature into macrophages, which can phagocytose 0x-LDL and further differentiate into vesicular cells, a process that causes extracellular matrix deposition and the proliferation and migration of adjacent vascular smooth muscle cells (VSMCs), leading to the formation of fibrous plaques. Plaque formation in the vasculature causes luminal narrowing, reduced blood flow, and ultimately tissue ischemia. If the risk factors for the development of atherosclerosis persist, there is a recurrent damage-repair process that results in the thinning of the fibrous cap, lipid pools, and the necrotic core of the atheromatous plaque, which eventually progresses to an unstable plaque. In the presence of hemodynamic changes, the arterial endothelium can retract and thus its continuity can be interrupted, eventually exposing the subendothelial tissue. This can activate platelets in the blood, causing them to adhere to the intima and form wall thrombi. Unstable (vulnerable) plaques are characterized by a thin fibrous cap, a large lipid pool that is prone to rupture, and the presence of numerous macrophages and a small number of smooth muscle cells. Plaque rupture is the result of a number of factors.²³

Atherosclerotic plaque rupture

Atherosclerotic plaques are composed of extracellular lipid particles, foam cells, and debris that accumulate within the intima of the arterial wall and form a lipid or necrotic core. The core is enveloped by a layer of collagen-rich matrix and smooth muscle cells covered by endothelial cells, termed the fibrous cap. Infiltration of inflammatory cells (mainly T cells and macrophages) occurs with the promotion of plaque progression and thrombosis, which in turn leads to acute intravascular events. The two most common causes of thrombosis are plaque rupture and surface erosion. The plaque ruptures when the fibrous cap covering the surface of the necrotic core splits, exposing the highly thrombogenic core to blood flow. Plaque erosion is caused by endothelial injury or exfoliation and overlying thrombus formation without significant rupture of the fibrous cap. Plaques prone to erosion tend to have high proteoglycan contents and low lipid contents, usually without significant infiltration of inflammatory cells. If plaque rupture or erosion occurs in an environment that is conducive to thrombosis, occlusive thrombosis results and can, in turn, cause acute symptomatic vascular events. In other settings where antithrombotic factors predominate, this can inhibit thrombosis and promote plaque healing.²⁴ Atherosclerosis is a disseminated process that begins in early childhood and develops asymptomatically in adulthood. In later life, it is clinically manifested by ischemic coronary syndromes, stroke, and peripheral arterial disease. So-called cardiovascular risk factors, including hyperlipidemia, hypertension, diabetes, and tobacco, have a significant impact on the progression of atherosclerosis.²⁵

Factors affecting the stability of atherosclerotic plaque

Factors affecting the stability of atherosclerotic plaques include both internal and external factors. The internal factors mainly include the density of new blood vessels, the size of eccentric lipids in plaques, inflammation, the thickness of the surface fiber cap, and the contents of smooth muscle cells and macrophages. External factors refer essentially to changes in mechanical and shear stress caused by hemodynamics.^26,27 The combination of these internal and external factors determines whether the plaque ruptures or not, with the internal factors often playing a leading role. The present review mainly discusses the influence of internal factors on the stability of atherosclerotic plaque.

Neovascularization and plaque stability

Angiogenesis refers to the process in which endothelial cells form new blood vessels. This is based on the original vessels and involves both budding and non-budding. In atherosclerosis, due to the reduced blood supply within the plaque, long-term hypoxia and inflammation can induce angiogenesis, resulting in the growth of blood vessels into the plaque under the control of the vascular endothelial growth factor signaling pathway.²⁸ Neovascular endothelial cells are loosely connected and are highly permeable, which is conducive to the exchange of blood oxygen. However, neovascular endothelial cells are both structurally simple and extremely fragile, making them easy to rupture and increasing the instability of the plaque. It has been found that the density of new blood vessels in ruptured atherosclerotic plaques is significantly higher than that in unruptured plaques, and the density of new blood vessels was observed to be positively correlated with plaque stability.²⁹ Ross et al.³⁰ believed that angiogenesis is an important marker for the transformation of atherosclerotic stable plaque to unstable plaque; thus, the investigation of factors associated with the angiogenesis pathway would be helpful for the development of drugs to stabilize plaque, which is extremely important for the prevention of atherosclerotic complications.

Inflammatory response and plaque stability

Atherosclerosis is a chronic inflammatory disease and inflammation is involved in the pathophysiological process of atherosclerosis.³¹ In the initial stages, ox-LDL represents the main initiator, and its cytotoxic effect can damage vascular endothelial cells directly, leading to changes in endothelial permeability, resulting in the passage of lipids and cellular components through the damaged endothelium and their subsequent deposition in the intima. Furthermore, the oxidation of low-density lipoprotein cholesterol (LDL-c), as well as the influence of monocyte chemotactic protein 1 and platelet-derived growth factor, alters the lymphocyte and monocyte composition of the overall blood leukocyte content within the damaged skin adhesion, leading to aggregation and leukocyte adhesion under the influence of inflammatory cytokines in the blood vessels, resulting in chronic inflammation. In addition, monocytes can transform into monocyte macrophages under the stimulation of monocyte chemotactic protein 1, and the latter can transform into macrophage-derived foam cells through surface receptor-mediated phagocytosis of ox-LDL, occurring at advanced stages of atherosclerosis.³² The inflammatory environment leads to lipid modification, resulting in increased cytotoxicity, together with the rupture of foam cells, necrosis, and disintegration within the lipid core of the atherosclerotic plaque. In addition, macrophages produce a variety of inflammatory cytokines, such as C-reactive protein, tumor necrosis factor α(TNF-α), and interleukin-6 (IL-6), which induce the production of regulatory molecules. The latter enter the bloodstream to further drive the progression of atherosclerotic plaque. The inflammatory response can also increase plaque instability and accelerate its rupture. On the one hand, the inflammatory response can lead to increased activation of endothelial cells and increased production of cell adhesion molecules, leading to the increased formation of foam cells, thus increasing the amount of lipid within the plaque and increasing the volume of the lipid core. On the other hand, the inflammatory response can also promote the proliferation of macrophages and the activation and secretion of interferon γ, which inhibits smooth muscle cell proliferation and collagen fiber synthesis. In addition, inflammation can induce vasospasm and increase plaque instability by affecting plaque mechanics.³³ Stable angina pectoris can evolve into unstable angina pectoris or even acute myocardial infarction, reflecting the transformation of atherosclerotic plaques from stable to unstable plaques. The expression levels of inflammatory cytokines are often used to evaluate the presence and strength of the inflammatory response. Studies have found that the expression levels of IL-6 and TNF-α in patients with stable angina pectoris are significantly lower than those in patients with unstable angina pectoris. The levels of IL-6 and TNF-α in patients with unstable angina pectoris were found to be significantly lower than those in patients with acute myocardial infarction, indicating that plaque stability was closely related to the inflammatory response.^34,35

Smooth muscle cells, macrophages, and endothelial cells are associated with plaque stability

Mature atheromatous plaques consist of a soft atheromatous substance rich in lipids (the necrotic lipid core) and a fibrous cap. It has been found that the fibrous cap is mainly composed of dense collagen fibers, scattered vascular smooth muscle cells, macrophages, and a small amount of elastic fibers, while unstable plaque frequently has a thin fibrous cap.³⁶ Vascular smooth muscle cells can produce interstitial glue to increase the stability of atherosclerotic plaques, while macrophages can release a variety of matrix metalloproteinases (MMPs), such as MMP-9 and MMP-2. These enzymes can hydrolyze interstitial collagen and extracellular matrix components to reduce the stability of plaques. Therefore, the contents of smooth muscle cells and macrophages in plaques are also important factors affecting plaque stability.^37,38 It was found that the apoptosis rate of smooth muscle cells in plaques of patients with unstable angina patients was higher than that in patients with stable angina, and reduced macrophage apoptosis may contribute to plaque stability.^39,40 In addition, vascular smooth muscle cells can also affect plaque stability by influencing vascular remodeling, inflammation, calcification, and other factors associated with the plaque. Macrophages can also transform into foam cells and phagocytose lipids to increase the volume of the lipid core, leading to reduced plaque stability.

Low-density lipoprotein and plaque stability

Low-density lipoprotein plays an important role in plaque stability. When there is an excess of LDL, especially ox-LDL, the cholesterol is deposited on the artery walls, resulting in atherosclerotic changes. Several studies have shown that plaques with a lipid core volume greater than 40% of the total plaque volume are more likely to rupture.⁴¹ Studies have also shown that LDL levels are closely associated with the stability of atherosclerotic plaque. Oxidized LDL can not only stimulate the production of adhesion molecules by endothelial cells but can also cause the adhesion and aggregation of monocytes and macrophages, resulting in inflammatory reactions. Macrophages attached to the damaged endothelium can also phagocytose ox-LDL to form foam cells, and the substances released after the foam cells burst are important components of the lipid core.⁴² In addition, ox-LDL can also be used as an antigen to stimulate the body to produce antibodies. Studies have found that the levels of anti-oxidant LDL antibodies are significantly elevated in acute myocardial infarction and unstable angina pectoris, indicating that LDL is likely to shift the balance towards unstable plaque.⁴³

The relationship between microRNA and plaque stability

microRNAs are documented to be involved in various diseases and can also indirectly affect the stability of plaque by regulating the above factors.⁴⁴

MicroRNAs are associated with angiogenesis in atherosclerosis

Neovascularization in atherosclerotic plaque mainly involves vascular endothelial cells, which can regulate the proliferation and migration of endothelial cells, affecting both their structure and function.⁴⁵ The DICER enzyme is a crucial endonuclease involved in the formation of all microRNAs. It was found that DICER-knockout mice died due to dysangiogenesis. Further studies showed that miR-126-knockout mice could not form a complete vascular system, thus miR-126 was considered a key regulator of vascular development.^46,47 Vascular endothelial growth factor plays a key role in angiogenesis and microRNAs have been shown to regulate vascular endothelial growth factor both directly and indirectly, thus influencing angiogenesis. Studies have shown that miR-92a-3p regulates retinal angiogenesis in vascular endothelial cells by targeting SGK3⁴⁸ while miR-181-b reduced angiogenesis by inhibiting the proliferation and migration of senescent endothelial cells.⁴⁹ MMP inhibitors have also been shown to have anti-angiogenic effects, and miR-181 can affect the proliferation of vascular endothelial cells and the formation of vascular networks by inhibiting MMP.⁵⁰ Current studies have also found that miR-130a, miR-210, miR-217, miR-92a, miR-378, miR-296, miR-130, miR-23, and miR-27 can promote angiogenesis (Table 1). However, miR-17 and miR-20, miR-20a, miR-21, miR-15, miR-16, miR-221, miR-222, and miR-503 inhibited angiogenesis (Table 2).

Table 1.

Promote angiogenesis-associated microRNAs.

microRNA	Angiogenesis-related function	Targets
microRNA-130a	Modulates endothelial cells to promote angiogenic phenotype	GAX and HOXA5⁵¹
microRNA-210	Promote endothelial cell migration and capillary-like structure	Ephrin-A3 and HIF-1α⁵²
microRNA-378	Promote angiogenesis	SuFu and Fus-1⁵³
microRNA-296	Promote endothelial cell migration and lumen formation	HGS⁵⁴
microRNA-23 /27	Promote blood vessel budding and macular angiogenesis	Sprouty2 and Sema6A⁵⁵

Table 2.

Inhibition angiogenesis-associated microRNAs.

microRNA	Angiogenesis-related function	Targets
microRNA-17 /20	Inhibit angiogenesis	Jak1⁵⁶
microRNA-21	Inhibit cell proliferation, migration and lumen formation	RHoB⁵⁷
microRNA-221 /222	Inhibit endothelial cell migration and proliferation	c-kit and eNOS⁵⁸
microRNA-503	Inhibit angiogenesis	cdc25A and CCNE1⁵⁹

GAX-growth arrest specific homeobox; HOXA5-homeobox A5; HIF-1α-hypoxia-inducible factor 1 alpha; SuFu-suppressor of fused; JAK1-Janus kinase; eNOS-endothelial nitric oxide synthase.

MicroRNAs are associated with inflammatory responses in atherosclerosis

Inflammation is not only involved in the development and progression of atherosclerosis but also plaque rupture. In atherosclerosis, multiple signaling pathways mediate inflammation, including the mitogen-activated protein kinase pathway, toll-like receptor signaling pathway, and reactive oxygen species signaling pathway, and the role of microRNAs in the regulation of inflammation is mainly to regulate the expression of proteins associated with these signaling pathways. Nuclear factor-κB (NF-κB) is a transcription factor affecting the expression of many inflammation-associated genes and can be regulated by various signaling pathways such as those associated with mitogen-activated protein kinases and reactive oxygen species. Activation of NK-κB leads to the increased production of TNF-α, IL-6, IL-1β, and other inflammatory cytokines. However, the activity of NF-κB is affected by NF-κB kinase inhibitors, which are key targets of miR-223.⁶⁰ In addition, miR-9 can exert anti-inflammatory effects by inhibiting the expression of NF-κB p50 by acting on the microRNA-κB p50 subunit of NF-κB.⁶¹ ETS is a transcription factor that regulates the inflammatory response in endothelial cells, and miR-221 has been shown to regulate ETS-1, thereby inhibiting monocyte adhesion molecules.^62,63 MicroRNA-21 increases the levels of several pro-inflammatory targets including VCAM-1, which in turn enhances the dysfunction of the endothelial cell layer to attract leukocytes, further increasing the likelihood of atherosclerotic plaque development.⁶⁴ Other microRNAs involved in the regulation of inflammatory response in atherosclerosis are miR-146a, miR-21, miR-155, miR-126, microRNA-145, and miR-19 (Table 3).

Table 3.

microRNAs associated with inflammation in atherosclerosis.

microRNA	Mechanism or pathway	Targets
microRNA-146a	Reduced macrophage maturation and promote vascular smooth muscle cell proliferation	CD80, CD86, eNOS, and cyclinD1⁶⁵
microRNA-21	Affects foam cell formation and phagocytosis and inhibition of macrophage phagocytosis	MKK3⁶⁶
microRNA-155	Inhibition of macrophage inflammatory response and lipid swallowing eats, and cell autophagy	CARHSP1 and SRA⁶⁷
microRNA-126	Endothelial cells autophagy	TNF-6, IL-6, and ICAM-1⁶⁸
microRNA-145	Inhibition of vascular smooth muscle cell proliferation and migration	ROCK1, NF-κB, p-STAT3, and ac-p65⁶⁹
microRNA-19	Increase macrophage migration inhibitor	HMG, CXCL1, and ABCA1⁷⁰

SRA-steroid receptor activator; TNF-6-tumor necrosis factor 6; IL-6-interleukin 6; ICAM-1-intercellular cell adhesion molecule; ROCK1-Rho-associated kinase 1; NF-κB-nuclear factor kappa-B; p-STAT3-p-signal transducers and activators of transcription.

MicroRNAs in vascular smooth muscle cells, macrophages, and endothelial cells

Vascular smooth muscle cells and macrophages play important roles in the stability of atherosclerotic plaques. MicroRNAs can indirectly affect the stability of plaques by regulating both these cell types. Studies have shown that miR-21 can promote the proliferation of vascular smooth muscle cells, while overexpression of miR-221 and miR-222 can promote the mitotic proliferation of these cells. miR-29 can target DNA methyltransferases responsible for the methylation of the MMP-9 and MMP-2 genes, influencing their expression and promoting the migration of vascular smooth muscle cells and accelerating plaque rupture. miR-155 can enhance the stability of atherosclerotic plaques, which may be related to inhibiting macrophage-mediated degradation of the plaque fibrous cap.⁷¹ miR-124 can inhibit the differentiation of monocytes into macrophages and reduce the risk of plaque rupture by targeting the inhibition of CCAAT enhancer binding protein α.⁷² microRNA-22 is thought to affect phenotypic changes by influencing the expression of three genes, namely, MECP2 (methyl CpG binding protein 2), HDAC4 (histone deacetylase 4), and EVI1 (ecotropic viral integration site 1). microRNA-22 influences changes in smooth muscle cells, from contractility to synthesis, most likely through the inhibition of its target genes MECP2, HDAC4, and EVI1.⁷³ MicroRNAs can also accelerate endothelial cell senescence by affecting endothelial cell function, a phenomenon that has the potential to exacerbate the development of atherosclerosis. In addition, microRNAs can also control the inflammatory state of blood vessels by affecting the activation and infiltration of leukocytes in the vessel walls. Studies have shown that inhibition of miR-126 leads to increased expression of the pro-inflammatory TNF-α which increases NF-κB and stimulates VCAM-1 activity, thereby increasing leukocyte-endothelial cell interactions and thus contributing to the development of atherosclerotic lesions.^74,75 In addition, miR-19 was found to inhibit the activity of SOCS3 in perivascular adipose tissue, promote the secretion of inflammatory cytokines and the invasion of macrophages into the endothelial cell layer, and promote the progression of atherosclerotic lesions.⁷⁶

MicroRNAs and lipid metabolism

Lipids are closely associated with atherosclerosis, and the concept of lipoprotein dysregulation in the pathogenesis of atherosclerosis has been widely recognized. This is shown by the establishment of animal models of atherosclerosis through the feeding of high-fat diets. Studies have shown that unstable atherosclerotic plaques often have large lipid cores, indicating that lipid is also a factor affecting the stability of atherosclerotic plaques. microRNAs can regulate lipid metabolism. When the body is subjected to various stimuli, the level of lipid-related microRNA in the body may increase or decrease. These changes in lipid-related microRNAs can affect the activities and functions of various enzymes and factors in lipid metabolic pathways, thus influencing lipid metabolism. microRNA-122 is the first microRNA that has been found to be able to regulate fat metabolism.⁷⁷ Deficiencies in enzymes related to fat metabolism in miR-122-deficient mice affect lipid synthesis. Furthermore, miR-33 has been shown to play a significant role in fat metabolism, where it regulates anti-Saccharomyces cerevisiae antibody gene targeting and ni man horse disease gene 1 expression to influence cholesterol metabolism pathways, as well as influencing beta oxidation-related gene expression levels to affect the fatty acid and three acyl glycerin metabolic pathways.⁷⁸ In addition, miR-370, miR-103, miR-107, miR-758, and miR-106b were all found to regulate lipid metabolism. Disordered lipid metabolism can cause the formation of excessive levels of ox-LDL, leading to increased phagocytosis of the ox-LDL by macrophages and thus promoting the enlargement of the lipid core volume of atherosclerotic plaque.

Future directions

microRNAs are closely associated with the stability of atherosclerotic plaques and may thus represent a new target for predicting plaque stability. Overexpression or downregulation of several microRNAs can increase plaque stability, providing a new direction for the development of plaque stabilization drugs. However, the ways in which microRNAs modulate the stability of atherosclerotic plaques are complex, with different microRNAs having different regulatory sites. However, with advances in genetic engineering and medical technology, investigation into the regulatory mechanisms of microRNAs on the stability of atherosclerotic plaque will result in greater progress.

Conclusions

MicroRNAs play significant roles in the pathophysiology of atherosclerosis by regulating the levels of post-transcriptional gene expression, thereby affecting the levels of intracellular proteins. This can lead to imbalances in endothelial cells, smooth muscle cells, and white blood cells, thereby inducing and increasing the growth of atherosclerotic plaques.

Footnotes

Authors’ contributions

The author confirms being the sole contributor of this work and has approved it for publication.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Availability of data and materials

Data available within the article.

ORCID iD

Pan Huang

References

Bentzon

Otsuka

Virmani

, et al. (2014) Mechanisms of plaqueformation and rupture. Circulation Research 114: 1852–1866.

Yang

Wang

Zeng

, et al. (2013) Rapid health transition in China,1990-2010: findings from the global burden of disease study 2010. Lancet 381(9882): 1987–2015.

Guo

, et al. (2021) Molecular imaging and non-molecular imaging of atherosclerotic plaque thrombosis. Frontiers in Cardiovascular Medicine 8: 692915–692915.

Joaquim

VHA

Pereira

Fernandes

, et al. (2023) Circular RNAs as a diagnostic and therapeutic target in cardiovascular diseases. International Journal of Molecular Sciences 24: 2125.

Thavarajah

, et al. (2018) Impact of miRNA in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 38(9): e159–e170.

LewisBurge

BPCB

Bartel

(2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15–20.

Macvanin

Obradovic

Zafirovic

, et al. (2023) The Role of miRNAs in Metabolic Diseases. Current Medicinal Chemistry 30: 1922–1944.

Zhang

, et al. (2021) Research advances for exosomal miRNAs detection in biosensing: From the massive study to the individual study. Biosensors & Bioelectronics 177: 112962.

Lee

Yuan

Kerr

, et al. (2020) Strategies to modulate MicroRNA functions for the treatment of cancer or organ injury. Pharmacological Reviews 72: 639–667.

10.

Kalantari

Chiang

Corey

(2016) Regulation of mammalian transcription and splicing by Nuclear RNAi. Nucleic Acids Research 44: 524–537.

11.

Hochreuter

Dall

Treebak

, et al. (2022) MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives. Molecular Metabolism 65: 101581.

12.

Zhang

Huang

, et al. (2022) Research progress about microRNAs involved in plant secondary metabolism. International Journal of Biological Macromolecules 216: 820–829.

13.

Ying

Lin

(2005) Intronic microRNAs. Biochemical and Biophysical Research Communications 326(3): 515–520.

14.

Carthew

Sontheimer

(2009) Origins and mechanisms of miRNAs and siRNAs. Cell 136(4): 642–655.

15.

Catalanotto

Cogoni

Zardo

(2016) MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions. International Journal of Molecular Sciences 17(10): 1712.

16.

Sheu- Gruttadauria

MacRae

(2017) Structural foundations of RNA silencing by Argonaute. Journal of Molecular Biology 429(17): 2619–2639.

17.

Wang

Liu

, et al. (2019) Effects of the PIWI/MID domain of Argonaute protein on the association of miRNAi' s seed base with the target. RNA 25(5): 620–629.

18.

Shao

Wang

Chen

, et al. (2019) Survey of miRNA- miRNA cooperative regulation principles across cancer types. Briefings in Bioinformatics 20(5): 1621–1638.

19.

Chen

Zh ong

(2020) miR- 124 and miR- 203 synergistically inactivate EMT pathw ay via coregulation of ZEB2 in clear cell renal cell carcinoma (ccRCC). Journal of Translational Medicine 18(1): 69.

20.

Liep

Kilic

Meyer

, et al. (2016) Cooperative Effect of miR-141- 3p and miR- 145- 5p in the regulation of targets in clear cell renal cell carcinoma. PLoS One 11(6): e0157801.

21.

Hansen

Wiklund

Bramsen

, et al. (2011) miRNAdependent gene silencing involving Ago2- mediated cleavage of a circular antisense RNA. The EMBO Journal 30(21): 4414–4422.

22.

Dai

Sh u

(2020) Retraction: Hsa_circ_0003645 shows an oncogenic role by sponging microRNA-1299 in hepatocellular carcinoma cells. Journal of Clinical Laboratory Analysis 34(6): e23249.

23.

JainWuPisapia

MBD

Salvatore

Mukherjee

, et al. (2017) A component-by-component characterisation of high-risk atherosclerotic plaques by multiphoton microscopic imaging. Journal of Microscopy 268(1): 39–44.

24.

Vergallo

Crea

(2020) Atherosclerotic plaque healing. The New England Journal of Medicine 383: 846–857.

25.

Libby

(2001) Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104: 365–372.

26.

Chen

Wang

(2016) Intraplaque Neovascularization and Its Influence on Stability of Atherosclerosis Plaque. Chinese Journal of Arteriosclerosis 24(3): 311–341.

27.

(2016) Stability of inflammatory markers and carotid artery plaque. Advances in Cardiovascular Disease 37(3): 219–224.

28.

Wang

Zhang

, et al. (2022) Loss of OTUD6B stimulates angiogenesis and promotes diabetic atherosclerosis. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 15: 3027–3038.

29.

Yang

Zhu

, et al. (2015) Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway. American Journal of Physiology, Endocrinology and Metabolism 308(4): 257–269.);E.

30.

Ross

Stagliano

Donovan

, et al. (2001) Atherosclerosis: a cancer of the blood vessels? American Journal of Clinical Pathology 116: S97–S107.

31.

Raheem Lateef Al-Awsi

Hadi Lafta

Hashim Kzar

, et al. (2022) PCSK9 pathway-noncoding RNAs crosstalk: Emerging opportunities for novel therapeutic approaches in inflammatory atherosclerosis. International immunopharmacology 113: 109318.

32.

Norata

Ballantyne

Catapano

(2013) New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. European Heart Journal 34(24): 1783–1789.

33.

Ammirati

Moroni

Magnoni

, et al. (2015) The role of T and B cells in human atherosclerosis and atherothrombosis. Clinical and Experimental Immunology 179(2): 173–187.

34.

Poredos

Spirkoska

Lezaic

, et al. (2017) Patients with an inflamed atherosclerotic plaque have increased levels of circulating inflammatory markers. Journal of Atherosclerosis and Thrombosis 24(1): 39–46.

35.

Fong

Few

See Too

, et al. (2015) Systemic and coronary levels of CRP,MPO,sCD40L and PlGF in patients with coronary artery disease. BMC Research Notes 8(1): 679–686.

36.

Huang

Chen

et al. (2022) Increased proximal wall shear stress of basilar artery plaques associated with ruptured fibrous cap. Brain Sciences 12(10): 1397. DOI: 10.3390/brainsci12101397.

37.

Seime

van Wanrooij

Karlöf

, et al. (2022) Biomechanical assessment of macro-calcification in human carotid atherosclerosis and its impact on smooth muscle cell phenotype. Cells 11: 3279. DOI: 10.3390/cells11203279.

38.

Wang

, et al. (2022) Early assessment of atherosclerotic lesions and vulnerable plaques in vivo by targeting apoptotic macrophages with AV nanobubbles. International Journal of Nanomedicine 17: 4933–4946.

39.

Hamed

Fattah

(2015) Clinical relevance of matrix metalloproteinase 9 in patients with acute coronary syndrome. Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 21(8): 705–711.

40.

Fang

Liu

(2010) Research progress on the relationship between apoptosis and atherosclerosis. Journal of Southeast University 29(1): 107–110.

41.

Zhou

Wang

Sun

, et al. (2021) Assessment of therapeutic response to statin therapy in patients with intracranial or extracranial carotid atherosclerosis by vessel wall MRI: a systematic review and updated meta-analysis. Frontiers in Cardiovascular Medicine 8: 742935.

42.

Nimkuntod

Tongdee

(2015) Association between subclinical atherosclerosis among hyperlipidemia and healthy subjects. Journal of the Medical Association of Thailand 98(Suppl 4): S51–S57.

43.

PatelZhang

VAQJ

Siddle

Soos

, et al. (2001) Defect in insulin-like growth factor1survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells is mediated by reduced surface binding and signaling. Circulation Research 88(9): 895–902.

44.

Rost

Wolf

Kase

, et al. (2001) Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 32: 2575–2579.

45.

Ren

Han

, et al. (2011) MicroRNAs in the pathogenesis of atherosclerosis. Chinese Journal of Biochemistry and Molecular Biology 27(6): 511–515.

46.

Yang

, et al. (2005) Dicer is required for embryonic angiogenesis during mouse development. The Journal of Biological Chemistry 280(10): 9330–9335.

47.

Cui

(2017) microRNANA-126 and vascular homeostasis. New Medicine 48(3): 143–147.

48.

Cui

Liu

Hong

, et al. (2022) MicroRNA-92a-3p Regulates Retinal Angiogenesis by Targeting SGK3 in Vascular Endothelial Cells. Investigative Ophthalmology & Visual Science 63: 19.

49.

Wang

Cen

Yang

, et al. (2021) miR-181a, delivered by hypoxic PTC-secreted exosomes, inhibits DACT2 by downregulating MLL3, leading to YAP-VEGF-mediated angiogenesis. Molecular Therapy. Nucleic Acids 24: 610–621.

50.

Zhou

Zou

(2017) MicroRNA-181 inhibits proliferation and promotes apoptosis of chondrocytes in osteoarthritis by targeting PTEN. Biochemistry and Cell Biology 95: 437–444.

51.

Chen

Gorski

(2008) Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 111(3): 217–226.

52.

Huang

, et al. (2010) MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 122(11 Suppl): 124–131.

53.

Lee

Deng

Wang

, et al. (2007) MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression .Proceedings of the National Academy of Sciences of the United States of America 104(51): 350-355.

54.

Wurdinger

Tannous

Saydam

, et al. (2008) miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 14(5): 382–393.

55.

Zhou

Gallagher

Ufret-Vincenty

, et al. (2011) Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23∼27∼24 clusters. Proceedings of the National Academy of Sciences of the United States of America 108(20): 287–292.

56.

Doebele

Bonauer

Fischer

, et al. (2010) Members of the microR- NA-17-92 cluster exhibit a cell-intrinsic, antiangiogenic function in endothelial cells. Blood 115(23): 944–950.

57.

Sabatel

Malvaux

Bovy

, et al. (2011) MicroRNA-21 exhibits anti- angiogenic function by targeting RhoB expression in endothelial cells. PLoS One 6(2): e16979.

58.

Dentelli

Rosso

Orso

, et al. (2010) microRNA-222 controls neo- vascularization by regulating signal transducer and activator of tran- scription 5A expression. Arteriosclerosis, Thrombosis, and Vascular Biology 30(8): 562–568.

59.

Caporali

Meloni

Völlenkle

, et al. (2011) Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 123(3): 282–291.

60.

Zhang

Zhu

Dai

, et al. (2021) MicroRNA-223 Suppresses IL-1β and TNF-α Production in Gouty Inflammation by Targeting the NLRP3 Inflammasome. Frontiers in Pharmacology 12: 637415.

61.

Deng

Chen

Liu

, et al. (2019) Silencing circular ANRIL protects HK-2 cells from lipopolysaccharide-induced inflammatory injury through up-regulating microRNA-9. Artificial Cells, Nanomedicine, and Biotechnology 47: 3478–3484.

62.

Lai

Lee

Tzu-Lin

Chang

, et al. (2020) MicroRNA-221/222 Mediates ADSC-Exosome-Induced Cardioprotection Against Ischemia/Reperfusion by Targeting PUMA and ETS-1. Frontiers in Cell and Developmental Biology 8: 569150.

63.

Verjans

Peters

Tim

Beaumont

, et al. (2018) MicroRNA-221/222 family counteracts myocardial fibrosis in pressure overload-induced heart failure. Hypertension 71: 280–288.

64.

Staszel

Zapała

Polus

, et al. (2011) Role of microRNAs in endothelial cell pathophysiology. Polskie Archiwum Medycyny Wewnetrznej 121: 361–366.

65.

Wang

Zhao

, et al. (2016) oxidized low-density lipoprotein up-regulates microRNA-146a via JNK and NF-κB signaling. Molecular Medicine Reports 13(2): 1709–1716.

66.

Feng

Deng

, et al. (2014) miR-21 attenuates lipopolysaccharide-induced lipid accumulation and inflammatory response: potential role in cerebrovascular disease. Lipids in Health and Disease 13: 27.

67.

Virtue

Johnson

Lopez-Pastraña

, et al. (2017) MicroRNA-155 defi- ciency leads to decreased atherosclerosis, increased white adipose tissue obesity, and non-alcoholic fatty liver disease: a novel mouse model of obesity paradox. The Journal of Biological Chemistry 292(4): 1267–1287.

68.

Zhang

(2018) miR-126 in peripheral blood mononuclear cells negatively correlates with risk and severity and is associated with inflammatory cytokines as well as intercellular adhesion molecule-1 in patients with coronary artery disease. Cardiology 139(2): 110–118.

69.

Sun

Zheng

, et al. (2018) Microrna-145 accelerates the inflam- matory reaction through activation of NF-κB signaling in athero- sclerosis cells and mice. Biomedicine & Pharmacotherapy 103: 851–857.

70.

Akhtar

Hartmann

Karshovska

, et al. (2015) Endothelial hypoxia-inducible factor-1α promotes atherosclerosis and monocyte recruitment by upregulating MicroRNA-19a. Hypertension 66(6): 1220–1226.

71.

Huang

Zhang

, et al. (2011) miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood 117(16): 4293–4303.

72.

Ponomarev

E D

Veremeyko

Barteneva

, et al. (2011) MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nature Medicine 17(1): 64–70.

73.

Yang

Chen

, et al. (2018) miR-22 is a novel mediator of vascular smooth muscle cell phenotypic modulation and neointima formation. Circulation 137: 1824–1841.

74.

Pérez-Sánchez

Aguirre

MÁ

Ruiz-Limón

, et al. (2017) Ubiquinol effects on antiphospholipid syndrome prothrombotic profile: a randomized, placebocontrolled trial. Arteriosclerosis, Thrombosis, and Vascular Biology 37: 1923–1932.

75.

Desjarlais

Dussault

Dhahri

, et al. (2017) MicroRNA-150 modulates ischemia-induced neovascularization in atherosclerotic conditions. Arteriosclerosis, Thrombosis, and Vascular Biology 37: 900–908.

76.

Zhang

, et al. (2018) Endothelial microparticles-mediated transfer of microRNA-19b promotes atherosclerosis via activating perivascular adipose tissue inflammation in apoE-/- mice. Biochemical and Biophysical Research Communications 495: 1922–1929.

77.

Peng

, et al. (2022) MicroRNA-122-5p Inhibition Improves Inflammation and Oxidative Stress Damage in Dietary-Induced Non-alcoholic Fatty Liver Disease Through Targeting FOXO3. Frontiers in Physiology 13: 803445.

78.

Xie

Peng

Guo

, et al. (2021) MicroRNA-33-5p inhibits cholesterol efflux in vascular endothelial cells by regulating citrate synthase and ATP-binding cassette transporter A1. BMC Cardiovascular Disorders 21: 433.